Russell Investments Group Ltd. cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 203,767 shares of the biopharmaceutical company's stock after selling 26,384 shares during the period. Russell Investments Group Ltd. owned about 0.20% of Regeneron Pharmaceuticals worth $154,406,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at about $26,000. Armstrong Advisory Group Inc. grew its stake in Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 28 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Trust Co. of Vermont acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider directly owned 47,833 shares in the company, valued at $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph J. Larosa sold 4,466 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total value of $4,311,878.34. Following the transaction, the executive vice president directly owned 38,906 shares of the company's stock, valued at $37,563,353.94. This trade represents a 10.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 27,028 shares of company stock worth $25,025,950. 6.97% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an "equal weight" rating in a research report on Monday, November 2nd. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 20th. Piper Sandler lifted their price target on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an "overweight" rating in a research note on Monday, October 19th. Finally, Evercore upped their price target on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an "outperform" rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $898.97.
Read Our Latest Stock Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Price Performance
REGN stock opened at $955.47 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The firm has a fifty day moving average price of $816.17 and a two-hundred day moving average price of $747.36. The firm has a market cap of $98.84 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 1.26 and a beta of 0.10.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping analysts' consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion for the quarter, compared to analysts' expectations of $4.58 billion. During the same period in the prior year, the company earned $11.83 earnings per share. The firm's revenue was up 36.3% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.30%.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company's medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
Further Reading
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.